Schizophrenia is recognized to be a highly heterogeneous disease at various levels, from
genetics to clinical manifestations and treatment sensitivity. This heterogeneity is also …

A growing body of evidence has emerged demonstrating a pathological link between
oxidative stress and schizophrenia. This evidence identifies oxidative stress as a …

Early detection and intervention in schizophrenia requires mechanism-based biomarkers
that capture neural circuitry dysfunction, allowing better patient stratification, monitoring of …

Despite loss of grey matter volume and emergence of distinct cognitive deficits in young
adults diagnosed with schizophrenia, current treatments for schizophrenia do not target …

A significant proportion of the global burden of disease can be attributed to mental illness.
Despite important advances in identifying risk factors for mental health conditions, the …

Perineuronal nets (PNNs) are specialized structures of the extracellular matrix that surround
the soma and proximal dendrites of certain neurons in the central nervous system …

Paranoia is a frequent and highly distressing experience in psychosis. Models of paranoia
suggest limbic circuit pathology. Here, we tested whether resting-state functional …

Treatment of schizophrenia (SCZ) historically relies on the use of antipsychotic drugs to treat
psychosis, with all of the currently available antipsychotics acting through the antagonism of …

Alzheimer's disease (AD) is the most common form of dementia worldwide, and it contributes
up to 70% of cases. AD pathology involves abnormal amyloid beta (Aβ) accumulation, and …

Emerging research on neuroplasticity processes in psychosis spectrum illnesses—from the
synaptic to the macrocircuit levels—fill key gaps in our models of pathophysiology and open …